Marco Exams automatically processes transurethral biopsies, urine cytology, IHC and NGS for FGFR2/3 results in Bladder Cancer to generate differential diagnoses, prognostic stratification and therapeutic suggestions. The system transforms laboratory and pathology reports into structured, evidence-based clinical recommendations.
Some answers to questions we often receive
Marco Exams integrates transurethral biopsies, urine cytology, IHC and NGS for FGFR2/3 results for Bladder Cancer, including immunohistochemistry, FISH, next-generation sequencing (NGS), liquid biopsy (ctDNA) and imaging results when available in structured format, generating integrated clinical interpretation of all results.
Yes. Marco Exams connects via standard APIs (HL7 FHIR, ASTM) with leading LIS and LIMS systems. The integration allows Bladder Cancer exam reports to flow automatically into Marco Exams, generating real-time clinical interpretation without manual intervention.
Yes. Marco Exams identifies Bladder Cancer result patterns requiring urgent clinical action — an acquired resistance mutation, a molecular result indicating ineligibility for a planned therapy, or an unexpected actionable alteration — and generates directed alerts to the treating physician.
Marco Exams has an interpretation engine trained on Bladder Cancer-specific biomarkers: T stage, histologic grade, FGFR2/3 mutations/fusions and PD-L1. For each marker, the system knows positivity thresholds per international guidelines, current therapeutic implications and complementary testing recommendations when results are borderline or unexpected.
Marco Exams' evidence engine updates continuously with reference guidelines for Bladder Cancer and published clinical trial data. FDA and EMA approvals and NCCN/ESMO guideline changes are systematically incorporated into the interpretation engine.
Marco Exams generates structured reports in PDF or web format, designed for direct presentation at Bladder Cancer tumor boards. The report integrates all patient exam results, clinical interpretation, prognostic stratification and recommended therapeutic options with their evidence sources.
Transurethral biopsy reports do not always include all relevant NCCN risk factors, generating incomplete staging that affects management.